Literature DB >> 30105082

Corrigendum to "Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition".

Ping Zhao1, Ke-Li Chen1, Guo-Li Zhang1,2, Guang-Rui Deng1,2, Juan Li1,3.   

Abstract

[This corrects the article DOI: 10.1155/2017/2103254.].

Entities:  

Year:  2018        PMID: 30105082      PMCID: PMC6076896          DOI: 10.1155/2018/9705495

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


In the article titled “Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition” [1], there was a missing grant number. Accordingly, the Acknowledgments section should be corrected as follows: This work was funded by China Postdoctoral Science Foundation (2016M601237), the Natural Science Foundation Project (30470193), the Scientific Research Foundation Project of the Education Department of Hubei Province (Q20142007), Natural Science Foundation of Hubei Province (2013CFC055), and the Young Plan Project of Hubei University of Chinese Medicine (XJ2014KJ008).
  1 in total

1.  Pharmacological Basis for Use of Selaginella moellendorffii in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition.

Authors:  Ping Zhao; Ke-Li Chen; Guo-Li Zhang; Guang-Rui Deng; Juan Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-05       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.